🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Michael Wang, MD discusses progress in the field of treating #MCL, and the results of the SYMPATICO clinical trial which assessed the efficacy of #ibrutinib combined with #venetoclax among newly diagnosed patients. Learn more: hubs.ly/Q03x61_r0

Consolidative thoracic radiotherapy following first-line treatment with chemoimmunotherapy improved intrathoracic control among patients with extensive-stage #SCLC. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

Amrita Krishnan, MD, FACP, participated in a debate covering new data on the use of stem cell #transplantation for patients with #MM at the 2025 Great Debates in Hematologic Malignancies meeting. Learn more: hubs.ly/Q03xxwzd0

Join us July 31 (12 PM ET) for the final EP-NEC webinar. ✔ Clinical distinctions ✔ DLL3 & immunotherapy ✔ 0.75 CE credit hubs.ly/Q03xx_HZ0

According to results from a phase 3 trial, #A140 plus #mFOLFOX6 demonstrated encouraging efficacy and safety compared to #cetuximab plus #mFOLFOX6 among patients with RAS wild-type #mCRC. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

A quadruplet therapy of subcutaneous #daratumumab in addition to #bortezomib, thalidomide, and dexamethasone demonstrated promising efficacy and safety among patients with newly diagnosed #MM. Learn more: hubs.ly/Q03xLHqk0

Tarun Wasil, MD, discusses treatment initiation and #discontinuation for patients with #MM in various stages at the 2025 Great Debates in Hematologic Malignancies meeting. Learn more: hubs.ly/Q03xQLDL0

Daehyun Lee, MD, discusses results from a retrospective cohort study which found that pulmonary #hypertension is prevalent among patients with #myelofibrosis and is associated with increased cardiovascular morbidity, including heart failure. Learn more: hubs.ly/Q03y0RvY0

According to a retrospective study, non–cancer-related mortality makes up a substantial proportion of deaths among patients with metastatic differentiated thyroid cancer. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

According to a retrospective analysis, HER2 status did not impact treatment outcomes with CDK4/6 inhibitors among patients with HR-positive, HER2-negative metastatic breast cancer. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

#Venetoclax plus #bortezomib and dexamethasone treatment demonstrated inferior overall survival and superior progression-free survival for patients with relapsed/refractory #MM compared to patients treated with placebo. Learn more: hubs.ly/Q03y0YtX0

According to results from the phase 3 #INDIGO trial, #vorasidenib demonstrated clinical promise among patients with residual or recurrent grade 2 IDH-mutant glioma. Learn more: hmpgloballearningnetwork.com/site/onc/news/… #medtwitter #onctwitter

At the EHA 2025 Congress, Raul Cordoba shared results from the EPCORE NHL-2 trial which evaluated the efficacy of #epcoritamab combined with R-ICE therapy for patients with relapsed/refractory #DLBCL. Learn more: hubs.ly/Q03y0S340

Only 1 week left until our final live session on Extra-Pulmonary Neuroendocrine Carcinoma. July 31 at 12:00 PM ET 45 minutes | 0.75 credit This is your last opportunity to attend live. Reserve your spot now: hubs.ly/Q03xy05j0

According to results from a real-world study, compassionate use of #lurbinectedin demonstrated both efficacy and safety among previously treated patients with extensive-stage small cell lung cancer. Learn more: hubs.ly/Q03yvPp60 #medtwitter #onctwitter

Rajshekhar Chakraborty, MD shares results from the LINKER-MM2 trial which assessed the safety and efficacy of #linvoseltamab plus #carfilzomib for patients with heavily pretreated relapsed/refractory #MM. Learn more: hubs.ly/Q03y137T0

For patients with high-risk smoldering #MM, fixed-duration #daratumumab has been approved by the European Commission based on results from the AQUILA phase 3 clinical trial. Learn more: hubs.ly/Q03yP7n00

The European Commission has approved #ibrutinib combined with chemoimmunotherapy for #MCL based on results from the phase 3 TRIANGLE clinical trial which demonstrated superior survival outcomes compared with current standard of care. Learn more: hubs.ly/Q03yP98Z0

Results from a phase 2 clinical trial highlight the impact of combining #nivolumab with #relatlimab on the tumor microenvironment in previously treated patients with unresectable or metastatic pMMR colorectal cancer. Learn more: hubs.ly/Q03yvZXZ0 #medtwitter #onctwitter

The combination of #venetoclax with CPX-351, a liposome of cytarabine and daunorubicin, demonstrated clinical activity among patients with relapsed/refractory #AML, according to results from a phase 2 trial. Learn more: hubs.ly/Q03y15TL0